Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.
The treatment combines an mRNA shot with Merck's Keytruda.
Overview
A late-stage trial that combined a messenger ribonucleic acid (mRNA) shot jointly developed by Moderna (NASDAQ:MRNA) and Merck with Merck’s Keytruda yielded strong results in what's being viewed as a potential game-changing cancer treatment.
The Phase 3 trial enrolled over 1,100 patients with melanoma whose tumors had been completely removed by surgery.
Details
Patients who received the personalized vaccine alongside Keytruda went longer before their cancer returned, and longer before it spread to distant parts of the body, than patients who received Keytruda alone.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.